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Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312 S297%¼(weight bearing of right leg) / (right + left leg) x100}, and swelling
score {swelling % ¼ (circumference of right knee - left knee) / (left
knee+ left knee) x100} of rabbits were observed once a week. At 42
days after surgery, animals were painlessly sacriﬁced and degenera-
tive changes in their femoral and tibial cartilages were graded
histopathologically.
Results: cPA stimulated HA synthesis of articular chondrocytes as
time and dose-dependent manner in vitro. 50 microM cPA increased
HA production three times more than control at 48 hours. HAS2 gene
was up-regulated as dose-dependent manner and kept increased
through the time. HAS1 and HAS3 up-regulated temporally at 2 hours
after addition, but down at 4 hours. There was no difference from
control on HYAL expression. In vivo study, cPA-treated rabbit showed
signiﬁcant less pain score (20% more weight bearing than control),
and dramatic reduce of swelling score than control (p¼0.0164). The
histological score of cartilage degeneration was signiﬁcantly less with
cPA administration (cPA 8.332.51 vs .control 14.332.33;
p¼0.0649).
Conclusions: These results indicated that cPA had stimulatory effects
on HA synthesis by articular chondrocytes in vitro. In vivo study using
rabbit experimental OA model indicated that cPA not only had stimu-
latory effects on endogenous HA synthesis, but also might have anti-
nociceptive and anti-inﬂammatory effect, and was very effective in
suppression of cartilage degeneration in early OA. Molecular mecha-
nism of cPA to prevent cartilage degeneration remains to be elucidated,
however, further study should be warranted for cPA as a novel candi-
date for therapeutic agent of OA.
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EFFECT OF SELF ASSEMBLED PEPTIDE-MESENCHYMAL STEM CELL
COMPLEX ON DELAYING THE PROGRESSION OF OSTEOARTHRITIS
S. Kim y, S. Lee y, Y. Jung z, J. Kim z, S. Kim z. y Samsung Med. Ctr., Seoul, ,
Republic of Korea; zKorea Inst. of Sci. and Technology, Seoul, , Republic
of Korea
Purpose: To ﬁnd the therapeutic effect of self-assembled peptide (SAP)
- mesenchymal stem cell (MSC) complex on delaying the progression of
osteoarthritis in animal model
Methods: Twenty three 12-week old Sprague-Dawley rats with
transected anterior cruciate ligament and medial meniscectomy were
used for the osteoarthritis model. They were randomly divided into 4
groups including control group. Mesenchymal stem cell, SAP, and
SAP-MSC complex were injected into their arthritic joints respec-
tively 3 weeks after the surgical induction of osteoarthritis. Nano-
structured SAP consisting of 12 amino-acids (KLD-12) was prepared
and used as a hydrogel scaffold which promotes articular tissue
response and provides proper microenvironment for MSC recruit-
ment and differentiation. Behavioral studies (number of rears and
stride length) were done before and 6 weeks after the injection and
the changes were calculated. Histologic examination (modiﬁed
Mankin score), measurement of cytokine level in joint ﬂuid (IL-1b
and TNF-a), and micro-CT analysis (bone mineral density and semi-
quantitative arthritis grade) were conducted 6 weeks after the
injection to ﬁnd their effect on delaying the progression of osteoar-
thritis. Analysis of variance (ANOVA) test was done to ﬁnd the group-
difference.
Results: Analysis of variance test found signiﬁcant group difference
(P¼.003) in modiﬁed Mankin score, and post-hoc Duncan test revealed
that the modiﬁed Mankin score was signiﬁcantly lower in SAP group
than in control group (P¼.002). Neither the number of rears nor the
stride length were signiﬁcantly different between all groups (P¼.912
and .300). The bone mineral density and arthritis grade from micro-CT
images were not signiﬁcantly different in all groups (P¼.052 and .780).
The level of IL-1b in joint ﬂuid was signiﬁcantly lower in SAP group than
in control group (P¼.037), while TNF-a did not show any signiﬁcant
group difference (P¼.344).
Conclusions: Self-assembled peptide (SAP) may promote the
articular tissue response by itself through IL-1b recruitment and
modify the balance between degeneration and regeneration of the
articular cartilage in osteoarthritis. However, SAP has little thera-
peutic role as a scaffold for exogenous MSC injection in treating
osteoarthritis.Ă
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Study Characteristics
Study Treatment Dose N
Adams et al., 1995 USA Synvisc 3 weekly IA injections 25
Usual NSAID
therapy
Usual dose (x12wk) 32
Altman et al., 1998 USA Hyalgan 5 weekly IA injections 16
Naproxen 500 mg orally twice daily (x12 wk)* 16
Dickson et al., 2001 UK Synvisc 3 weekly IA injections 53
Diclofenac 100 mg orally once daily (x12 wk) 55
Petrella et al., 2002 Canada Suplasyn 3 weekly IA injections 25
Diclofenac 75 mg and 100 mg misoprostol
orally twice daily (x12wk)
26
Ishijima et al., 2012 Japan Suvenyl 5 weekly IA injections 91
Loxoprofen 60 mg orally thrice daily (x5 wk)** 80
Note: IA¼ intra-articular; wk ¼weeks; yr ¼ year; BMI ¼ Body Mass Index; VAS ¼ Visual
Index; nd ¼ no data; *subcutaneous sham injection; **no IA injection controlĂ
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HYALURONIC ACID: AS EFFECTIVE AS NSAIDS FOR KNEE
OSTEOARTHRITIS. A META-ANALYSIS
R.R. Bannuru y,z, E.E. Vaysbrot y, M. Agni y, M.C. Sullivan y, T.E.
McAlindon y. y Tufts Med. Ctr., Boston, MA, USA; z Sackler Sch. of
Graduate BioMed. Sci. Tufts Univ., Boston, MA, USA
Purpose: The efﬁcacy of intra-articular Hyaluronic acid (HA) for knee
osteoarthritis (OA) has been debated for over a decade. It has been
systematicallyevaluated inmeta-analyses,mostlyagainstplaceboor intra-
articular corticosteroids. However, it has never been compared in a meta-
analysis against oneof themost efﬁcacious andwidelyused treatments for
knee OA, i.e., NSAIDs. Furthermore, the favorable safety proﬁle of HA over
NSAIDs makes this comparison especially interesting. We aimed to assess
the efﬁcacy of HA in a pooled comparison to NSAIDs for knee OA.
Methods: We searched Medline, EMBASE, Google Scholar, ISI Web of
Science and Cochrane Database from inception to November 2012. We
also hand-searched review articles, manuscripts and supplements from
medical journals. We included all human randomized controlled trials
comparing HA with NSAIDs for knee OA. Two reviewers independently
performed data extraction and assessed the quality of each trial. We
computed effect sizes for pain, function, and stiffness (change from
baseline) for each study using the Hedges’ g statistic corrected for small
sample sizes. Effect sizes were pooled using random effects model.
Heterogeneity was assessed using I2 statistic. Sensitivity analysis was
performed by pooling trials reporting pain outcomes at 4 and 12 weeks
to check for the therapeutic trajectory.
Results: The 5 eligible trials included 712 participants (HA - 357;
NSAIDs - 355) with an age range of 61 to 67 years (Table 1). They were
published between 1995 and 2012. NSAIDs used in these trials were
from the same class. Four different HA preparations were used. Sample
sizes varied between 51 and 325. All trials except one were of 12 week
duration. Three had IA injections and one had subcutaneous injections
as control. Two trials were open-label. Dropout rates ranged from 2 to
30%. Five trials contributed to the pain analysis at last follow-up. Both
groups showed improvement from baseline. We found an effect size of
‑0.07 (95%CI -0.24, 0.10), not favoring either treatment (Table 2, Figure
1). There was no statistically signiﬁcant difference between the groups
at 4 and 12 weeks. Two trials contributed to the function and stiffness
analyses, and showed no statistically signiﬁcant differences between
the groups. Injection site pain was the most common adverse event
reported in the HA group, and gastrointestinal adverse events were
more common in the NSAIDs group.
Conclusions: This meta-analysis shows that HA injection is as
effective as continuous oral NSAIDs at 4 and 12 weeks. Given the
favorable safety proﬁle of HA over NSAIDs, this result is clinically
signiﬁcant and could transform knee OA care. Though some of the
trials may not have been powered to detect non-inferiority,
combining them increases the power for such an analysis. Our study
detected no safety concerns; however, the included trials had only
a short follow-up duration. Future randomized trials should incor-
porate a longer duration of follow-up and larger samples to fully
evaluate safety. It will be interesting to evaluate synergistic effect of
the two treatments.Age (yr) Female % BMI Duration (wk) Main Outcomes
61 68 27.0 12 VAS pain with motion
63 68 23.7
3 62 61 31.5 12 VAS pain on walking; WOMAC
pain, function, stiffness2 63 57 31.9
65 57 29.0 12 WOMAC pain, function,
stiffness; Lequesne Index64 55 29.0
67 36 29.5 12 WOMAC pain, function,
stiffness; VAS pain on walking66 42 29.4
nd nd nd 5 VAS pain
nd nd nd
Analogue Scale; WOMAC ¼Western Ontano & McMaster Universities Osteoarthritis
